[Authorized specifications for human use in clinical practice of radiopharmaceuticals composed of iobenguane (123I) marketed in Spain].
This article details the specifications authorised for human use in the clinical practice for the radiopharmaceutical products composed of iobenguane ((123)I) marketed in Spain.
Cortés-Blanco
A
A
Asesora y Evaluadora Clínica, Agencia Española de Medicamentos y Productos Sanitarios. acortesb@agemed.es
Martínez Lázaro
R
R
Vargas Castrillón
E
E
D019797:3-Iodobenzylguanidine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D000075202:Contraindications; D004285:Dogs; D062787:Drug Overdose; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D007774:Lactation; D007880:Legislation, Drug; D008297:Male; D008875:Middle Aged; D009683:Nuclear Medicine / Q000331:legislation & jurisprudence*; D011247:Pregnancy; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D051381:Rats; D013030:Spain; D055815:Young Adult
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine